Eli Lilly (LLY)

Explore how portfolio concentration and stock count set these healthcare ETFs apart, impacting risk and diversification for investors seeking sector exposure.

Portfolio size and stock selection set these healthcare ETFs apart and help shape their risk and return profiles.

All three could become highly prominent biotech companies within 10 years.

Even if a company is profitable, it doesn’t always mean it’s a great investment. Some struggle to maintain growth, face looming threats, or fail to reinvest ...

Compare portfolio strategies, cost structures, and risk profiles as two Invesco healthcare ETFs take different paths to sector exposure.

Eli Lilly has experienced robust growth, but investors may be thinking twice about the stock due to its high valuation.

Eli Lilly's Phase 3 BRUIN CLL-322 study showed Jaypirca combination therapy cut progression or death risk by 45% in CLL/SLL.

As the Q1 earnings season wraps, let’s dig into this quarter’s best and worst performers in the branded pharmaceuticals industry, including Royalty Pharma (N...

Let’s dig into the relative performance of Jazz Pharmaceuticals (NASDAQ:JAZZ) and its peers as we unravel the now-completed Q1 pharmaceuticals earnings seaso...

Eli Lilly is winning the GLP-1 race right now, but it isn't resting on its laurels.

The Vanguard Mega Cap Growth ETF owns a concentrated portfolio of America's largest companies.

The pharmaceutical company's flagship anti-obesity drug continues to bolster its efficacy and tolerability arguments.

Eli Lilly, Parker-Hannifin, and Microsoft all have grown their dividend by 50% or more over the past five years, but still have plenty of room for dividend growth.

New cancer therapies may help fund dividend growth.

Eli Lilly and American Express are top picks on CNBC's Halftime Report Final Trades. Live Nation is on the verge of a new 52-week high.

Viking stock is known for soaring after positive news.

A company that generates cash isn’t automatically a winner. Some businesses stockpile cash but fail to reinvest wisely, limiting their ability to expand. Cas...

Pfizer stock may not be cheap enough to buy yet, but it's certainly too cheap to sell.

Even if a company is profitable, it doesn’t always mean it’s a great investment. Some struggle to maintain growth, face looming threats, or fail to reinvest ...

The pharma giant is well-positioned to lead the $200 billion global obesity treatment market.

These stocks may deliver gains during any market environment.

Infectious disease could fuel Eli Lilly's next growth phase.

Marvell’s leap into the S&P 500 caps a sharp AI-chip rebound that helped steady U.S. stocks, today, June 8, 2026.